Alumis (ALMS) to Release Quarterly Earnings on Wednesday

Alumis (NASDAQ:ALMS) will likely be announcing its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.79) per share and revenue of $2.4930 million for the quarter. Investors may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, May 14, 2026 at 4:00 PM ET.

Alumis (NASDAQ:ALMS) last issued its quarterly earnings data on Thursday, March 19th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.05). The company had revenue of $1.93 million during the quarter, compared to the consensus estimate of $2.75 million. Alumis had a negative net margin of 1,011.75% and a negative return on equity of 116.97%. On average, analysts expect Alumis to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Alumis Price Performance

Shares of NASDAQ:ALMS opened at $26.13 on Wednesday. The firm has a 50 day simple moving average of $25.22 and a 200 day simple moving average of $17.98. The company has a market cap of $3.32 billion, a price-to-earnings ratio of -8.54 and a beta of -0.31. Alumis has a one year low of $2.76 and a one year high of $30.60.

Analysts Set New Price Targets

ALMS has been the subject of several analyst reports. Morgan Stanley raised their price target on shares of Alumis from $33.00 to $38.00 and gave the company an “overweight” rating in a research note on Friday, March 20th. UBS Group reaffirmed an “outperform” rating on shares of Alumis in a research note on Tuesday, January 6th. Leerink Partners raised their price target on shares of Alumis from $20.00 to $32.00 and gave the company an “outperform” rating in a research note on Tuesday, January 6th. Oppenheimer raised their price target on shares of Alumis from $50.00 to $55.00 and gave the company an “outperform” rating in a research note on Monday, March 30th. Finally, Guggenheim raised their price target on shares of Alumis from $18.00 to $32.00 and gave the company a “buy” rating in a research note on Wednesday, January 7th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Alumis presently has an average rating of “Moderate Buy” and an average target price of $38.60.

Institutional Investors Weigh In On Alumis

Large investors have recently modified their holdings of the company. Russell Investments Group Ltd. increased its position in shares of Alumis by 320.9% during the third quarter. Russell Investments Group Ltd. now owns 6,419 shares of the company’s stock worth $26,000 after buying an additional 4,894 shares during the period. New York State Common Retirement Fund increased its position in shares of Alumis by 173.7% during the second quarter. New York State Common Retirement Fund now owns 11,767 shares of the company’s stock worth $35,000 after buying an additional 7,467 shares during the period. BNP Paribas Financial Markets increased its position in shares of Alumis by 104.9% during the third quarter. BNP Paribas Financial Markets now owns 11,770 shares of the company’s stock worth $47,000 after buying an additional 6,027 shares during the period. The Manufacturers Life Insurance Company acquired a new stake in Alumis in the second quarter worth $56,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Alumis by 64.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,535 shares of the company’s stock worth $77,000 after purchasing an additional 4,926 shares during the period.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.